Jürgen Götz

Summary

Affiliation: University of Queensland
Country: Australia

Publications

  1. pmc Tau-targeted treatment strategies in Alzheimer's disease
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
    Br J Pharmacol 165:1246-59. 2012
  2. pmc Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models
    Janet van Eersel
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, Department of Pathology, University of Sydney, Camperdown, New South Wales 2050, Australia
    Proc Natl Acad Sci U S A 107:13888-93. 2010
  3. pmc Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease
    Yazi D Ke
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia
    PLoS ONE 7:e35678. 2012
  4. doi Brief update on different roles of tau in neurodegeneration
    Arne Ittner
    Brain and Mind Research Institute, University of Sydney, Camperdown, NSW 2050, Australia
    IUBMB Life 63:495-502. 2011
  5. doi Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains
    Janet van Eersel
    Discipline of Pathology, The University of Sydney, Sydney, NSW, 2006, Australia
    J Neural Transm 116:1243-51. 2009
  6. pmc Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice
    Mian Bi
    Laboratory for Translational Neurodegeneration, Brain and Mind Research Institute, The University of Sydney, Camperdown, New South Wales, Australia
    PLoS ONE 6:e26860. 2011
  7. pmc Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol
    Yun An Lim
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia
    PLoS ONE 6:e28887. 2011
  8. pmc Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease
    Yazi D Ke
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney, Australia
    PLoS ONE 4:e7917. 2009
  9. doi Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models
    Lars M Ittner
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney NSW 2050, Australia
    Cell 142:387-97. 2010
  10. doi Substrate-specific reduction of PP2A activity exaggerates tau pathology
    Natasha Deters
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown, NSW 2050, Australia
    Biochem Biophys Res Commun 379:400-5. 2009

Collaborators

Detail Information

Publications41

  1. pmc Tau-targeted treatment strategies in Alzheimer's disease
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
    Br J Pharmacol 165:1246-59. 2012
    ..We are reviewing the literature and discuss what can be expected regarding the translation into clinical practice and how the findings can be extended to other neurodegenerative diseases with protein aggregation in brain...
  2. pmc Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models
    Janet van Eersel
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, Department of Pathology, University of Sydney, Camperdown, New South Wales 2050, Australia
    Proc Natl Acad Sci U S A 107:13888-93. 2010
    ..Taken together, sodium selenate mitigates tau pathology in several AD models, making it a promising lead compound for tau-targeted treatments of AD and related dementias...
  3. pmc Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease
    Yazi D Ke
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia
    PLoS ONE 7:e35678. 2012
    ..Our findings add SFPQ to a growing list of transcription factors with an altered nucleo-cytoplasmic distribution under neurodegenerative conditions...
  4. doi Brief update on different roles of tau in neurodegeneration
    Arne Ittner
    Brain and Mind Research Institute, University of Sydney, Camperdown, NSW 2050, Australia
    IUBMB Life 63:495-502. 2011
    ..Furthermore, we review recent findings regarding the spreading of tau pathology throughout the brain as disease progresses...
  5. doi Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains
    Janet van Eersel
    Discipline of Pathology, The University of Sydney, Sydney, NSW, 2006, Australia
    J Neural Transm 116:1243-51. 2009
    ..Such differences in solubility and phosphorylation may contribute, at least in part, to the formation of distinct tau deposits, but may also have implications for the clinical differences between AD and PiD...
  6. pmc Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice
    Mian Bi
    Laboratory for Translational Neurodegeneration, Brain and Mind Research Institute, The University of Sydney, Camperdown, New South Wales, Australia
    PLoS ONE 6:e26860. 2011
    ..In addition, increased astrocytosis was found in the oldest treated group. Taken together, our data suggests that tau-targeted immunization slows the progression of NFT pathology in mice, with practical implications for human patients...
  7. pmc Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol
    Yun An Lim
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia
    PLoS ONE 6:e28887. 2011
    ..Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-out...
  8. pmc Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease
    Yazi D Ke
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney, Australia
    PLoS ONE 4:e7917. 2009
    ..Hence, DM can accelerate onset and increase severity of disease in individuals with a predisposition to developing tau pathology...
  9. doi Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models
    Lars M Ittner
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney NSW 2050, Australia
    Cell 142:387-97. 2010
    ..Our findings suggest that this dendritic role of tau confers Abeta toxicity at the postsynapse with direct implications for pathogenesis and treatment of AD...
  10. doi Substrate-specific reduction of PP2A activity exaggerates tau pathology
    Natasha Deters
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown, NSW 2050, Australia
    Biochem Biophys Res Commun 379:400-5. 2009
    ..This suggests that, in addition to kinases, PP2A and its regulatory subunits may be a therapeutic target for Alzheimer's disease...
  11. doi Role of hippocalcin in mediating Aβ toxicity
    Yun An Lim
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett St, Camperdown, NSW 2050, Australia
    Biochim Biophys Acta 1822:1247-57. 2012
    ..Our data suggest that hippocalcin has a neuroprotective role in AD, presenting it as a putative biomarker...
  12. pmc Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease
    Lars M Ittner
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney, Camperdown, New South Wales 2050, Australia
    J Biol Chem 284:20909-16. 2009
    ..Because JIP1 is involved in regulating cargo binding to kinesin motors, our findings may, at least in part, explain how hyperphosphorylated Tau mediates impaired axonal transport in AD and frontotemporal dementia...
  13. doi Animal models reveal role for tau phosphorylation in human disease
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown, New South Wales 2050, Australia
    Biochim Biophys Acta 1802:860-71. 2010
    ....
  14. pmc Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons
    Janet van Eersel
    Laboratory for Translational Neurodegeneration, Brain and Mind Research Institute, University of Sydney, Sydney, Australia
    PLoS ONE 6:e22850. 2011
    ..Taken together, our data suggests a role for the proteasome in subcellular localization of TDP-43, and possibly in disease...
  15. pmc Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia
    Lars M Ittner
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, NSW 2050, Australia
    Proc Natl Acad Sci U S A 105:15997-6002. 2008
    ..Distinct modes of transport are also impaired in sciatic nerves, which may explain amyotrophy. Together, the K3 mice are a unique model of FTD-associated Parkinsonism, with pathomechanistic implications for the human pathologic process...
  16. ncbi Alzheimer's disease selective vulnerability and modeling in transgenic mice
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney, NSW, Australia
    J Alzheimers Dis 18:243-51. 2009
    ..We suggest, since transgenic animal models of disease reproduce aspects of selective vulnerability, that these models offer a valuable system for future investigations into the physiological basis of selective vulnerability...
  17. doi Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease
    Lars M Ittner
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, The University of Sydney, Camperdown, 100 Mallett Street, NSW 2050, Australia
    Nat Rev Neurosci 12:65-72. 2011
    ..As we gain a deeper understanding of the different cellular functions of tau, the focus shifts from the axon, where tau has a principal role as a microtubule-associated protein, to the dendrite, where it mediates amyloid-β toxicity...
  18. ncbi A decade of tau transgenic animal models and beyond
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
    Brain Pathol 17:91-103. 2007
    ..Moreover, the existence of a number of neurodegenerative diseases with tau pathology in the absence of extracellular deposits underscores the relevance of research on tau...
  19. doi Functional genomics dissects pathomechanisms in tauopathies: mitosis failure and unfolded protein response
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
    Neurodegener Dis 5:179-81. 2008
    ..Furthermore, in cell culture, Abeta(42) induces tau aggregation. While both Abeta(42) and mutant tau cause neuronal dysfunction, their modes of action are only vaguely understood...
  20. doi Dissecting toxicity of tau and beta-amyloid
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, N S W, Australia
    Neurodegener Dis 7:10-2. 2010
    ..Major questions include (1) which aggregation state of Abeta confers toxicity, (2) do amyloidogenic proteins have similar mechanisms of toxicity, and (3) does soluble tau interfere with cellular functions?..
  21. ncbi Animal models of Alzheimer's disease and frontotemporal dementia
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown, NSW 2050, Australia
    Nat Rev Neurosci 9:532-44. 2008
    ..With advanced imaging techniques that can be used in both humans and mice an early, preclinical diagnosis of AD and FTD could be within reach...
  22. pmc ENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice
    Xin Liu
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown, NSW 2050, Australia
    J Biomed Biotechnol 2011:130947. 2011
    ..Together, we provide evidence for a real potential of an ENU mutagenesis to dissect motor functions in wild-type and tau mutant mice...
  23. pmc Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta
    Nicole Schonrock
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia
    PLoS ONE 5:e11070. 2010
    ..Taken together, our findings suggest that neuronal miRNA deregulation in response to an insult by Abeta may be an important factor contributing to the cascade of events leading to AD...
  24. ncbi Functional Genomics meets neurodegenerative disorders Part I: transcriptomic and proteomic technology
    Della C David
    Brain and Mind Research Institute, University of Sydney, 100 Mallett St, Camperdown, NSW 2050, Australia
    Prog Neurobiol 76:153-68. 2005
    ..These tools have been applied to a range of neurodegenerative disorders and are discussed and integrated in part II (Functional Genomics meets neurodegenerative disorders. Part II: application and data integration)...
  25. doi Decoding the non-coding RNAs in Alzheimer's disease
    Nicole Schonrock
    Victor Chang Cardiac Research Institute VCCRI, Darlinghurst, NSW 2010, Australia
    Cell Mol Life Sci 69:3543-59. 2012
    ..By understanding this intricate regulatory network, there is hope for a better understanding of disease mechanisms and ultimately developing diagnostic and therapeutic tools...
  26. ncbi Single nucleotide variants (SNVs) define senescence-accelerated SAMP8 mice, a model of a geriatric condition
    Fabien Delerue
    Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
    J Alzheimers Dis 36:349-63. 2013
    ..Our data present these genes for a more detailed analysis in aging and neurodegeneration studies. They underscore the usefulness of SAMP8 mice as an animal model to study fundamental mechanisms of both aging and the pathogenesis of AD...
  27. doi Divergent phosphorylation pattern of tau in P301L tau transgenic mice
    Natasha Deters
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett St, Camperdown, NSW 2050, Australia
    Eur J Neurosci 28:137-47. 2008
    ..Thus, differential regulation of phosphorylation is important for NFT formation in neurodegenerative diseases with tau pathology...
  28. doi Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction
    Yun An Lim
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, Australia
    Proteomics 10:1621-33. 2010
    ..In conclusion, our data suggest that A beta and HA both exert toxicity, at least in part, via mitochondrial dysfunction, thus restoring their function may be beneficial for both AD and T2DM...
  29. pmc Modes of Aβ toxicity in Alzheimer's disease
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, NSW 2050, Australia
    Cell Mol Life Sci 68:3359-75. 2011
    ..We also discuss the role of miRNAs in mediating the toxic effects of the Aβ peptide...
  30. ncbi Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods?
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
    J Alzheimers Dis 14:423-9. 2008
    ..We discuss ways of how tau aggregation is monitored in these mice and what the detection limits are of these methods. We conclude that new tools are needed to measure the different stages of tau aggregation...
  31. ncbi How it all started: tau and protein phosphatase 2A
    Chang Liu
    Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
    J Alzheimers Dis 37:483-94. 2013
    ....
  32. pmc PTL-1 regulates neuronal integrity and lifespan in C. elegans
    Yee Lian Chew
    School of Molecular Bioscience, University of Sydney, New South Wales, 2006, Australia
    J Cell Sci 126:2079-91. 2013
    ..Our data suggest that some of the effects of tau pathology result from the loss of physiological tau function and not solely from a toxic gain-of-function due to accumulation of tau...
  33. ncbi Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures
    Yun An Lim
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown, NSW 2050, Australia
    FEBS Lett 582:2188-94. 2008
    ..Depending on the cell type, this finding is also supported by co-incubation of human amylin and Abeta...
  34. ncbi Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, Sydney, NSW, Australia
    Med J Aust 185:381-4. 2006
    ..More than 50 drugs are currently in clinical trials, and novel and more effective drugs targeting both AD and FTD are expected to become available within 5-10 years...
  35. doi Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β
    Nicole Schonrock
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown, 2050, Camperdown, Sydney, NSW, Australia
    J Mol Neurosci 46:324-35. 2012
    ..Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis...
  36. doi Gateway-compatible lentiviral transfer vectors for ubiquitin promoter driven expression of fluorescent fusion proteins
    Niklas Krupka
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, The University of Sydney, 100 Mallett St, Camperdown, NSW 2050, Australia
    Plasmid 63:155-60. 2010
    ..Both pLVU/GFP and pLVU/RED can be utilized in different experiments, including protein localization studies and live-cell in vivo imaging...
  37. ncbi Pronuclear injection for the production of transgenic mice
    Lars M Ittner
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, 100, Mallett Street, Camperdown, New South Wales 2050, Australia
    Nat Protoc 2:1206-15. 2007
    ..Transgenic expression of a truncated form of the microtubule-associated protein tau (delta tau) is used as an example for the anticipated results...
  38. ncbi Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
    Jürgen Götz
    Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia
    J Neurochem 98:993-1006. 2006
    ..It will be challenging to determine the molecular mechanisms of these different axonopathies, as this might assist in the development of new therapeutic strategies...
  39. pmc An update on the toxicity of Abeta in Alzheimer's disease
    Jürgen Götz
    Alzheimer s and Parkinson s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, NSW, Australia
    Neuropsychiatr Dis Treat 4:1033-42. 2008
    ..We discuss which of these conformations exert toxicity, highlight molecular pathways involved and discuss what has been learned by applying functional genomics...
  40. pmc Profiling Murine Tau with 0N, 1N and 2N Isoform-Specific Antibodies in Brain and Peripheral Organs Reveals Distinct Subcellular Localization, with the 1N Isoform Being Enriched in the Nucleus
    Chang Liu
    Sydney Medical School, Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia
    PLoS ONE 8:e84849. 2013
    ..Together these findings reveal significant differences between the three murine tau isoforms that are likely to reflect different neuronal functions. ..
  41. pmc What Renders TAU Toxic
    Jürgen Götz
    Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia Sydney Medical School, Brain and Mind Research Institute, University of Sydney, Sydney, NSW, Australia
    Front Neurol 4:72. 2013
    ..However, what is toxic in one context may not be in another, and simply reducing, but not fully abolishing TAU levels may be sufficient to abrogate TAU toxicity...